TransMedics Group’s (TMDX) “Neutral” Rating Reiterated at JPMorgan Chase & Co.

JPMorgan Chase & Co. reissued their neutral rating on shares of TransMedics Group (NASDAQ:TMDX) in a research report report published on Tuesday morning, MarketBeat reports. JPMorgan Chase & Co. currently has a $75.00 target price on the stock, down from their previous target price of $116.00.

Several other equities analysts also recently issued reports on TMDX. Baird R W raised shares of TransMedics Group to a “strong-buy” rating in a research note on Tuesday, September 24th. Piper Sandler dropped their price target on TransMedics Group from $110.00 to $90.00 and set an “overweight” rating on the stock in a research note on Wednesday, December 11th. Needham & Company LLC reaffirmed a “hold” rating on shares of TransMedics Group in a research report on Wednesday, December 11th. Canaccord Genuity Group decreased their price target on shares of TransMedics Group from $109.00 to $104.00 and set a “buy” rating for the company in a research note on Wednesday, November 20th. Finally, TD Cowen cut their price objective on shares of TransMedics Group from $175.00 to $120.00 and set a “buy” rating on the stock in a research report on Monday, November 18th. Three equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $122.70.

TransMedics Group Stock Up 2.3 %

Shares of NASDAQ TMDX opened at $65.71 on Tuesday. The stock has a 50-day moving average price of $92.92 and a two-hundred day moving average price of $130.29. The company has a market cap of $2.21 billion, a price-to-earnings ratio of 69.90 and a beta of 2.06. TransMedics Group has a 12 month low of $60.80 and a 12 month high of $177.37. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings data on Monday, October 28th. The company reported $0.12 earnings per share for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The firm had revenue of $108.76 million for the quarter, compared to the consensus estimate of $115.00 million. During the same quarter in the prior year, the firm earned ($0.12) EPS. The company’s revenue was up 63.7% on a year-over-year basis. As a group, analysts forecast that TransMedics Group will post 1 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Tamer I. Khayal sold 1,084 shares of the company’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $86.40, for a total transaction of $93,657.60. Following the completion of the sale, the insider now owns 20,843 shares in the company, valued at approximately $1,800,835.20. This represents a 4.94 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Waleed H. Hassanein sold 8,625 shares of the firm’s stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $132.71, for a total value of $1,144,623.75. Following the transaction, the chief executive officer now owns 61,643 shares in the company, valued at approximately $8,180,642.53. This trade represents a 12.27 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 19,417 shares of company stock worth $2,240,738 in the last quarter. Insiders own 7.00% of the company’s stock.

Institutional Investors Weigh In On TransMedics Group

A number of institutional investors have recently added to or reduced their stakes in TMDX. Raymond James & Associates grew its holdings in shares of TransMedics Group by 152.4% in the second quarter. Raymond James & Associates now owns 23,444 shares of the company’s stock valued at $3,531,000 after acquiring an additional 14,156 shares in the last quarter. EFG Asset Management North America Corp. raised its stake in shares of TransMedics Group by 12.4% during the 2nd quarter. EFG Asset Management North America Corp. now owns 21,196 shares of the company’s stock worth $3,191,000 after purchasing an additional 2,343 shares during the period. SlateStone Wealth LLC purchased a new position in shares of TransMedics Group in the 2nd quarter worth about $856,000. HB Wealth Management LLC bought a new position in TransMedics Group during the second quarter valued at about $318,000. Finally, F M Investments LLC purchased a new stake in TransMedics Group during the second quarter worth about $10,957,000. 99.67% of the stock is owned by institutional investors.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.